| Title: | Identification and validation of putative therapeutic targets in respiratory disease |
| Lead Institution: | GlaxoSmithKline, UK |
| Principal investigator: | Dr Robert Scott |
Application 45243
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Therapies aimed at drug targets with support from genetic evidence are more likely to be both safe and effective. We aim to generate detailed knowledge on lung diseases using a broad range of data in UK Biobank and to perform genetic analyses of those diseases to support identification of the next generation of drug targets. This is an ongoing partnership between academic scientists at the Universities of Leicester and Nottingham and GlaxoSmithKline, where we aim to apply cutting edge scientific approaches, publish our findings for the benefit of the wider community and translate our findings towards new therapies to benefit patients.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 11521 | Genome-wide association study of chronic sputum production implicates loci involved in mucus production and infection | Richard J. Packer (+23) | 2023 | European Respiratory Journal |
Enabling scientific discoveries that improve human health